Andreas Goette
Corporate Officer/Principal chez OMEICOS Therapeutics GmbH
Provenance du réseau au premier degré de Andreas Goette
Entité | Type d'entité | Industrie | |
---|---|---|---|
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.
11
| Holding Company | Biotechnology | 11 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Andreas Goette via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
Freie Universität Berlin | College/University | Masters Business Admin Graduate Degree | |
Kyoto University | College/University | Undergraduate Degree | |
Coley Pharmaceutical GmbH
Coley Pharmaceutical GmbH Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Coley Pharmaceutical GmbH is a German company that provides research and development in the field of natural sciences, engineering, agricultural sciences and medicine. The company is based in Berlin, Germany. The company was founded by Heather L. Davis. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
The Rockefeller University | College/University | Corporate Officer/Principal | |
Institut Pasteur
Institut Pasteur Investment Trusts/Mutual FundsMiscellaneous The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
REDX PHARMA PLC | Pharmaceuticals: Major | Director/Board Member | |
BioMedx Group, Inc.
BioMedx Group, Inc. Medical SpecialtiesHealth Technology BioMedx Group, Inc. operates as a medical technology company transforming the cosmetic surgery consultation services. The firm engages in product development focus on the modeling and simulation of the human face for aesthetic and facial reconstruction applications. The company was founded by Rudy A. Mazzocchi and is headquartered in Baltimore, MD. | Medical Specialties | Director/Board Member | |
ENLIVEX THERAPEUTICS LTD. | Biotechnology | Director/Board Member | |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Medical/Nursing Services | Director/Board Member | |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Pharmaceuticals: Major | Director/Board Member | |
BioMed X GmbH
BioMed X GmbH Miscellaneous Commercial ServicesCommercial Services BioMed X GmbH is an independent research institute that conducts biomedical pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, and diagnostics. The private company is based in Heidelberg, Germany. The German company sponsors these projects with pharmaceutical partners such as Merck, Boehringer Ingelheim, Johnson & Johnson, AbbVie, and Roche. Talented early-career scientists from all over the world are recruited to work on these projects. The company combines crowdsourcing with local incubation to provide creative solutions to big biomedical research challenges. Each research team has access to state-of-the-art research infrastructure and is guided by experienced mentors from academia and industry. The company was founded in 2013 by Christian Tidona, who has been the CEO since 2013. | Miscellaneous Commercial Services | Director/Board Member | |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | Investment Managers | Consultant / Advisor | |
Coley Pharmaceutical Group, Inc.
Coley Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA | Pharmaceuticals: Major | Corporate Officer/Principal | |
Universität zu Köln | College/University | Doctorate Degree | |
Rigontec GmbH
Rigontec GmbH Pharmaceuticals: MajorHealth Technology Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany. | Pharmaceuticals: Major | Chief Executive Officer | |
BIO Deutschland
BIO Deutschland Miscellaneous Commercial ServicesCommercial Services BIO Deutschland is a business association for the biotechnology industry. The private company is based in Berlin, Germany. The German company was founded by Peter Heinrich, Horst Domdey. Viola Bronsema has been the CEO of the company since 2006. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
STipe Therapeutics ApS
STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | Pharmaceuticals: Major | Chairman | |
AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
ARIX BIOSCIENCE PLC | Investment Managers | Corporate Officer/Principal | |
Neovii Biotech GmbH
Neovii Biotech GmbH BiotechnologyHealth Technology Neovii Biotech GmbH develops and markets biopharmaceutical products in the field of transplantation. The company was founded in 2003 and is headquartered in Gräfelfing, Germany. | Biotechnology | Chief Executive Officer | |
PYXIS ONCOLOGY, INC. | Pharmaceuticals: Major | Director/Board Member | |
Twelve Bio
Twelve Bio Miscellaneous Commercial ServicesCommercial Services Part of Ensoma, Inc., Twelve Bio is a Danish company that seeks to expand the breadth of CRISPR-based gene-editing medicines to transform the management of serious diseases. The company is based in Copenhagen, Denmark. Twelve Bio uses its insights into nuclease structure and function to design highly precise and nimble CRISPR-Cas12 candidates for therapeutic application. The company will continuously advance its platform and understanding of Cas enzymes to address the needs of patients worldwide. The company was founded by Stefano Stella, Guillermo Montoya. Twelve Bio was acquired by Ensoma, Inc. on February 09, 2023. | Miscellaneous Commercial Services | Chairman | |
High-Tech Gründerfonds Management GmbH
High-Tech Gründerfonds Management GmbH Investment ManagersFinance High-Tech Gründerfonds Management GmbH (HTGF) is a venture capital firm founded in 2005. The firm is headquartered in Bonn, Germany. | Investment Managers | Private Equity Investor | |
Data Information Intelligence GmbH | Founder | ||
Universität Leipzig | College/University | Doctorate Degree | |
WMT AG
WMT AG Miscellaneous Commercial ServicesCommercial Services WMT AG is a German research company that specializes in developing cancer therapies. WMT was founded in 2020 by Yves Guillermet and Claus Kremoser, with Claus Kremoser serving as the CEO since 2020. | Miscellaneous Commercial Services | Director/Board Member | |
Humboldt-Universität zu Berlin | College/University | Doctorate Degree | |
Sanofi-Aventis Deutschland GmbH
Sanofi-Aventis Deutschland GmbH Pharmaceuticals: MajorHealth Technology Sanofi-Aventis Deutschland GmbH engages in the development, manufacture, and packaging of medicines, as well as pharmaceutical products. It also focuses on the research into the causes of diseases and the search for its drug treatment. The company was founded in 2004 and is headquartered in Frankfurt, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Universität Konstanz | College/University | Doctorate Degree | |
Actimis Pharmaceuticals, Inc.
Actimis Pharmaceuticals, Inc. BiotechnologyHealth Technology Actimis Pharmaceuticals, Inc. provides pharmaceutical research and development services. it focuses on the development of small therapeutics for respiratory and inflammatory disorders. The company was founded by Kevin B. Bacon in November 2004 and is headquartered in San Diego, CA. | Biotechnology | Director/Board Member | |
Mitsui & Co. Global Investment Ltd.
Mitsui & Co. Global Investment Ltd. Investment ManagersFinance Mitsui & Co. Global Investment Ltd is a private Equity/venture Capital firm, a subsidiary of Mitsui & Co., Ltd. founded in 1996. The firm is headquartered in Tokyo. | Investment Managers | Private Equity Investor | |
Mitsui & Co. Global Investment, Inc.
Mitsui & Co. Global Investment, Inc. Investment ManagersFinance Mitsui & Co. Global Investment, Inc. (Mitsui & Co. Global Investment) is a venture capital subsidiary of Mitsui Ventures founded in 1999. The firm is headquartered in Menlo Park, California. | Investment Managers | President | |
NapaJen Pharma, Inc.
NapaJen Pharma, Inc. Pharmaceuticals: MajorHealth Technology NapaJen Pharma, Inc. develops drug delivery technology solutions through cellular transport pathways. Its products include lead platform and drug delivery. The firm specializes in the development of novel drug delivery systems by utilizing natural transport pathways whose cells are used to move molecular cargo into themselves and across internal compartments. The company was founded by Dr. Kazuo Sakurai and Hironori Ando in December 2004 and is headquartered in Burlingame, CA. | Pharmaceuticals: Major | Director/Board Member | |
CANBAS CO., LTD. | Pharmaceuticals: Major | Director/Board Member | |
Anaeropharma Science, Inc.
Anaeropharma Science, Inc. BiotechnologyHealth Technology Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan. | Biotechnology | Director/Board Member | |
BIOAMBER INC. | Chemicals: Specialty | Director/Board Member | |
Hutchison MediPharma Ltd.
Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Medical Specialties | Director/Board Member | |
Boston Biomedical, Inc.
Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Miscellaneous Commercial Services | Director/Board Member | |
Inflectis Bioscience SAS
Inflectis Bioscience SAS BiotechnologyHealth Technology Inflectis Bioscience SAS develops therapeutics for the treatment of protein misfolding diseases. The firm engages in the development of new chemical series for the treatment of non-orphan diseases whose etiology also lies in the accumulation of misfolded proteins. The company was founded in September 2013 by Philippe Guedat and Pierre Miniou and is headquartered in Nantes, France. | Biotechnology | Director/Board Member | |
Université Libre de Bruxelles | College/University | Corporate Officer/Principal | |
Merck Serono SA
Merck Serono SA Medical SpecialtiesHealth Technology Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
Plant Genetic Systems International
Plant Genetic Systems International BiotechnologyHealth Technology Part of Bayer AG, Plant Genetic Systems International is a Dutch company that provides biological products. The company was founded by Daniel D. Adams. | Biotechnology | Corporate Officer/Principal |
Statistiques
Internationale
Allemagne | 16 |
Etats-Unis | 13 |
Japon | 5 |
Israël | 5 |
France | 4 |
Sectorielle
Health Technology | 24 |
Consumer Services | 10 |
Finance | 8 |
Commercial Services | 7 |
Miscellaneous | 2 |
Opérationnelle
Director/Board Member | 38 |
Corporate Officer/Principal | 12 |
Private Equity Investor | 5 |
Doctorate Degree | 5 |
Chairman | 4 |
Relations les plus connectées
Insiders | |
---|---|
Bernhard Kirschbaum | 15 |
Taro Inaba | 14 |
Gaston Matthyssens | 12 |
Christian Schetter | 12 |
Ute Mercker | 6 |
Martin Pfister | 5 |
Karen Uhlmann | 3 |
Peter Seiler | 2 |
Robert Fischer | 1 |
Wolf-Hagen Schunck | 1 |
Leonardo Caló | 1 |
- Bourse
- Insiders
- Andreas Goette
- Connexions Sociétés